Public Health England-Respiratory and Vaccine Preventable Bacteria Reference Unit, Colindale, London, UK.
Public Health England-Virus Reference Department, Colindale, London, UK.
J Med Microbiol. 2013 Sep;62(Pt 9):1281-1289. doi: 10.1099/jmm.0.062000-0. Epub 2013 May 30.
Recent vaccination with pertussis vaccine can confound serological and oral fluid (OF) assays targeting anti-pertussis toxin (anti-PT) IgG antibodies as a marker of recent infection. This study sought to establish the minimum potentially confounding time period based on experimental data to assist interpretation from such samples submitted from UK subjects for pertussis diagnosis. Anti-PT IgG antibody response and decay were measured post-vaccination using a modified OF IgG antibody-capture ELISA (GACELISA). Data were obtained from 72 infants after the third acellular pertussis vaccine dose in the primary schedule (4 months of age) and from 119 children after the single dose at preschool age (3 years 4 months to 5 years 8 months of age). Specimens were taken at approximately 1 month intervals for 9 months post-primary immunization (third dose) and 13 months post-preschool booster (PSB). The modified GACELISA demonstrated a sensitivity of 52/56 (92.9 %: 95 % CI 82.7-98.0) and a specificity of 120/128 (93.8 %: 95 % CI 88.0-97.3) and showed good agreement with the National Reference Laboratory standard anti-PT IgG serum ELISA (rank correlation = 0.80) and the original OF assay (rank correlation = 0.79). Modelling of the decline in antibody titres showed a reduction of 54 % and 34 % for each doubling of time after day 14 for the post-third primary dose and post-PSB subjects, respectively. These data suggest that the minimum confounding time period is approximately 300 days for samples obtained post-primary immunization and at least 3 years for samples submitted from UK children following immunization with the PSB. These data will greatly assist the interpretation of single high diagnostic anti-PT IgG titres by allowing an estimate of the positive predictive value, when the number of days post-immunization and prevalence are known or assumed.
最近接种百日咳疫苗会干扰针对抗百日咳毒素(anti-PT)IgG 抗体的血清学和口腔液(OF)检测,因为它是近期感染的标志物。本研究旨在根据实验数据确定最小的潜在干扰时间,以帮助解释从英国受试者提交的用于百日咳诊断的样本。使用改良的 OF IgG 抗体捕获 ELISA(GACELISA)在接种后测量抗-PT IgG 抗体的反应和衰减。从 72 名婴儿(4 个月龄)接受初级计划中的第三剂无细胞百日咳疫苗和 119 名儿童(3 岁 4 个月至 5 岁 8 个月龄)接受学龄前单次剂量后获得数据。在初次免疫(第三剂)后约 1 个月间隔采集标本 9 个月,在学龄前加强剂(PSB)后 13 个月采集标本。改良的 GACELISA 显示出 52/56(92.9%:95%CI82.7-98.0)的敏感性和 120/128(93.8%:95%CI88.0-97.3)的特异性,与国家参考实验室标准抗-PT IgG 血清 ELISA(等级相关=0.80)和原始 OF 检测(等级相关=0.79)具有良好的一致性。对抗体滴度下降的建模表明,在第 14 天之后,每增加一倍时间,第三次初级剂量后和 PSB 后受试者的抗体分别减少 54%和 34%。这些数据表明,对于初次免疫后获得的样本,最小的干扰时间约为 300 天,对于英国儿童在接受 PSB 免疫后提交的样本,至少为 3 年。当已知或假定免疫后天数和流行率时,这些数据将极大地帮助解释单次高诊断性抗-PT IgG 滴度,从而可以估计阳性预测值。